Table of Contents

State Plan Amendment (SPA) #: 17-0011

This file contains the following documents in order listed:

1. CMS Approval Letter
2. CMS Form 179
3. Attachment to Block 7 of CMS Form 179
4. Superseding Page Listing (Attachment to Blocks 8 & 9 of CMS Form 179)
5. Approved SPA Pages
September 22, 2017

Ms Jami Snyder
State Medicaid Director
Post Office Box 13247, MC: H-100
Austin, TX 78711

Dear Ms Snyder:

We have reviewed Texas's State Plan Amendment (SPA) 17-0011, Prescribed Drugs, received in the Dallas Regional Office on June 27, 2017.

This amendment is to bring the state plan into compliance with the applicable requirements of 42 Code of Federal Regulations (CFR) §447.518, relating to payment for covered outpatient drugs, specifically as it relates to addressing reimbursement methodology for 340B drugs, physician administered drugs, clotting factor, federal supply schedule and drugs purchased at nominal price. The proposed amendment does not affect previously approved pharmacy reimbursement components in SPA 15-005.

Based on the information provided and consistent with the regulations at 42 CFR 430.20, we are pleased to inform you that SPA 17-0011 is approved with an effective date of April 1, 2017. A copy of the signed CMS-179 form, as well as the pages approved for incorporation into Texas's state plan will be forwarded by the Dallas Regional Office.

If you have any questions regarding this amendment, please contact Pamela Schweitzer at (410) 786-2832 or pamela.schweitzer@cms.hhs.gov.

Sincerely,

/s/
John M. Coster, Ph.D., R.Ph.
Director, Division of Pharmacy

CC: Bill Brooks, ARA, CMS, Dallas Regional Office
    Billy Bob Farrell, CMS, Dallas Regional Office
    Ford Blunt, CMS, Dallas Regional Office
    Beren Dutra, Texas Health & Human Services
**TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL**

**FOR:** CENTERS FOR MEDICARE AND MEDICAID SERVICES

**TO:** REGIONAL ADMINISTRATOR

CENTERS FOR MEDICARE AND MEDICAID SERVICES

DEPARTMENT OF HEALTH AND HUMAN SERVICES

<table>
<thead>
<tr>
<th>1. TRANSMITTAL NUMBER:</th>
<th>2. STATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>17-0011</td>
<td>TEXAS</td>
</tr>
</tbody>
</table>

| 3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID) |

<table>
<thead>
<tr>
<th>4. PROPOSED EFFECTIVE DATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 1, 2017</td>
</tr>
</tbody>
</table>

5. TYPE OF PLAN MATERIAL (Circle One):

- ☑ NEW STATE PLAN
- ☐ AMENDMENT TO BE CONSIDERED AS NEW PLAN
- ☐ AMENDMENT

COMPLETE BLOCKS 8 THRU 10 IF THIS IS AN AMENDMENT (Separate Transmittal for each amendment)

<table>
<thead>
<tr>
<th>6. FEDERAL STATUTE/REGULATION CITATION:</th>
<th>7. FEDERAL BUDGET IMPACT:</th>
</tr>
</thead>
<tbody>
<tr>
<td>42 Code of Federal Regulations (CFR) §447.518</td>
<td>SEE ATTACHMENT</td>
</tr>
</tbody>
</table>

| a. FFY 2017 | $0 |
| b. FFY 2018 | $0 |
| c. FFY 2019 | $0 |

<table>
<thead>
<tr>
<th>8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:</th>
<th>9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable):</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEE ATTACHMENT TO BLOCKS 8 &amp; 9</td>
<td>SEE ATTACHMENT TO BLOCKS 8 &amp; 9</td>
</tr>
</tbody>
</table>

10. SUBJECT OF AMENDMENT:

The purpose of this amendment is to bring the state plan into compliance with the applicable requirements of 42 Code of Federal Regulations (CFR) §447.518, relating to payment for covered outpatient drugs.

11. GOVERNOR'S REVIEW (Check One):

- ☑ GOVERNOR’S OFFICE REPORTED NO COMMENT
- ☐ COMMENTS OF GOVERNOR’S OFFICE ENCLOSED
- ☐ NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

12. SIGNATURE OF STATE AGENCY OFFICIAL:

[Redacted]

13. TYPED NAME: Jami Snyder

14. TITLE: State Medicaid Director

15. DATE SUBMITTED: June 27, 2017

16. RETURN TO:

Jami Snyder
State Medicaid Director
Post Office Box 13247, MC: H-100
Austin, Texas 78711

FOR REGIONAL OFFICE USE ONLY

17. DATE RECEIVED: June 27, 2017

18. DATE APPROVED: September 22, 2017

19. EFFECTIVE DATE OF APPROVED MATERIAL: April 1, 2017

20. SIGNATURE OF REGIONAL OFFICIAL:

[Redacted]

21. TYPED NAME: Bill Brooks

22. TITLE: Associate Regional Administrator
Division of Medicaid and Children's Health

23. REMARKS:

**RECEIVED**

SEP 26 2017

OFFICE OF THE STATE MEDICAID DIRECTOR
Attachment to Block 7 of CMS Form 179
Transmittal Number 17-0011

<table>
<thead>
<tr>
<th>Total Fiscal Impact</th>
<th>Federal</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>FFY 2017</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>FFY 2018</td>
<td>$0</td>
<td>$0</td>
</tr>
<tr>
<td>FFY 2019</td>
<td>$0</td>
<td>$0</td>
</tr>
</tbody>
</table>

The proposed amendment is estimated to have no fiscal impact, as it is not expected to have an effect on Medicaid utilization or cost.

Access to Care

Access to care will not be affected and communications with providers will be maintained to address any concerns, should they arise.
Attachment to Blocks 8 & 9 of CMS Form 179

Transmittal Number 17-0011

<table>
<thead>
<tr>
<th>Number of the Plan Section or Attachment</th>
<th>Number of the Superseded Plan Section or Attachment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Attachment 4.19-B</td>
<td>Attachment 4.19-B</td>
</tr>
<tr>
<td>Page 2b</td>
<td>Page 2b (TN 15-0005)</td>
</tr>
<tr>
<td>Page 2c</td>
<td>Page 2c (TN 15-0005)</td>
</tr>
<tr>
<td>Page 2c.1</td>
<td>Page 2c.1 N/A - New Page</td>
</tr>
<tr>
<td>Page 2c.2</td>
<td>Page 2c.2 N/A - New Page</td>
</tr>
<tr>
<td>Page 2c.3</td>
<td>Page 2c.3 N/A - New Page</td>
</tr>
<tr>
<td>Page 2d</td>
<td>Page 2d (TN 15-0005)</td>
</tr>
</tbody>
</table>

State: Texas
Date Received: 6-27-17
Date Approved: 9-22-17
Date Effective: 4-01-17
Transmittal Number: 17-0011
Pharmacy Reimbursement Methodology

1. General

The upper limit for payment for prescribed drugs, whether legend or nonlegend items, will be based on the lower of the actual acquisition cost (AAC) plus a professional dispensing fee or the usual and customary charge, as defined and determined by the Texas Health and Human Services Commission (HHSC) or its designee. These provisions do not apply to payment for drugs included in a provider’s reimbursement formula, such as inpatient or bundled payments.
Pharmacy Reimbursement Methodology (continued)

2. **Reimbursement Methodology:**

   HHSC or its designee reimburses contracted Medicaid pharmacy providers according to the professional dispensing fee formula defined in this section.

   The professional dispensing fee is determined by the following formula: Professional Dispensing Fee = (((Actual Acquisition Cost + fixed component) divided by (1 – the percentage used to calculate the variable component)) - AAC) + delivery incentive + preferred generic incentive.

   (a) **Drug Ingredient Cost**

   AAC is defined in Section IIC (Legend and Nonlegend Medications).

   (b) **Professional Dispensing Fee Determination**

   (1) The fixed component is $7.93.

   (2) The variable component is 1.96%.

   (3) The total professional dispensing fee shall not exceed $200 per prescription.

   (4) A delivery incentive shall be paid to approve providers who certify a form prescribed by HHSC or its designee that the delivery services meet minimum conditions for payment of the incentive. These conditions include: making deliveries to individuals rather than just to institutions, such as nursing homes; offering no-charge prescription delivery to all Medicaid recipients requesting delivery in the same manner as to the general public; and publicly displaying the availability of prescription delivery services at no charge. The delivery incentive is $0.15 per prescription and is to be paid on all Medicaid prescriptions filled. This delivery incentive is not to be paid for over-the-counter drugs, which are prescribed as a benefit of this program.

   (5) A preferred generic incentive of $0.50 per prescription shall be paid on all Medicaid prescriptions filled for preferred generic drugs for which a manufacturer has agreed to pay a supplemental rebate. Preferred generic drugs are subject to the requirements for placement on the Preferred Drug List (PDL).
Pharmacy Reimbursement Methodology (continued)

(c) Legend and Nonlegend Medications

For all medications, legend and nonlegend, covered by the Vendor Drug Program (VDP) and appearing in the Texas Drug Code Index (TDCI) and updates, the following requirements must be met:

(1) A participating pharmacy is reimbursed based on the lesser of AAC plus a Professional Dispensing Fee per prescription, or the usual and customary price charged the general public.

(2) AAC is defined as the Texas Retail Pharmacy Acquisition cost (RetailPAC); long-term care pharmacy acquisition cost (LTCPAC); specialty pharmacy acquisition cost (SPAC); or the 340B price (see subsection (F) of this section). Pharmacies subject to LTCPAC are "Long-term care (LTC) pharmacies." LTC Pharmacies serve LTC Patients, as determined by the Single State Agency, and must be "closed door pharmacies." Closed door pharmacies do not have public-facing operations and do not accept outpatient walk-in patients.

(A) AAC is verifiable by invoice audit conducted by HHSC to include necessary supporting documentation that will verify the final cost to the provider.

(B) The RetailPAC, LTCPAC, and SPAC will be based on the National Average Drug Acquisition Cost (NADAC) as defined here:

RetailPAC: Ingredient cost = NADAC
LTCPAC: Ingredient cost = (NADAC - 2.4%)
SPAC: Ingredient cost = (NADAC - 1.7%)

(C) If NADAC is not available for a specific drug, the RetailPAC, LTCPAC, and SPAC will be defined as follows:

RetailPAC: Ingredient cost = (WAC - 2%)
LTCPAC: Ingredient cost = (WAC - 3.4%)
SPAC: Ingredient cost = (WAC - 8%)

(D) If NADAC OR WAC is not available for a specific drug, the ingredient cost will be based on pharmacy invoice.

(E) In compliance with 42 Code of Federal Regulations (C.F.R.) §§447.512 and 447.514, reimbursement for drugs subject to Federal Upper Limits (FULs) may not exceed FULs in the aggregate.
Pharmacy Reimbursement Methodology (continued)

(c) Legend and Nonlegend Medications (continued)

(F) The reimbursement for 340B covered entities that fill prescriptions for Medicaid recipients with drugs purchased under Section 340B of the Public Health Services Act ("Section 340B") is AAC, up to the 340B ceiling price, plus a professional dispensing fee per prescription. The state defines AAC as follows:

**NEW DRUG PRICING**
BRAND/GENERIC: WAC minus 23.1 percent

**ESTABLISHED DRUG PRICING**
BRAND/GENERIC DRUGS (excluding HIV PRODUCTS and HEMOPHILIA PRODUCTS): WAC minus 57 percent

HIV PRODUCTS: WAC minus 40 percent
HEMOPHILIA PRODUCTS: WAC minus 32 percent

(G) 340B covered entities that fill prescriptions for Medicaid recipients with covered outpatient drugs not purchased under Section 340B are reimbursed at AAC, plus HHSC’s professional dispensing fee. AAC for covered outpatient drugs not purchased under Section 340B, as defined at Section 2(c)(2), is based on NADAC or WAC. If WAC is not available, the ingredients cost will be determined using pharmacy invoice.

(H) A contracted pharmacy under contract with a 340B covered entity described in section 1927(a)(5)(B) of the Social Security Act that fill prescriptions for Medicaid recipients with drugs purchased under Section 340B will be reimbursed at AAC, up to the 340B ceiling price, as defined as section 2(c)(2)(F), plus the professional dispensing fee.
Pharmacy Reimbursement Methodology (continued)

(c) Legend and Nonlegend Medications (continued)

(I) Indian Health Service (IHS), Tribal, and Urban Indian Organizations (I/T/U) that fill prescriptions for Medicaid recipients are reimbursed AAC, plus HHSC’s professional dispensing fee per prescription. AAC for covered outpatient drugs not purchased under Section 340B, as defined at Section 2(c)(2), is based on NADAC or WAC. If WAC is not available, the ingredients cost will be determined using pharmacy invoice.

(J) Drugs acquired at the Federal Supply Schedule (FSS) are reimbursed AAC plus HHSC’s professional dispensing fee per prescription.

(K) Drugs acquired at the Nominal Price are reimbursed AAC plus HHSC’s professional dispensing fee per prescription.

(L) Reimbursement for physician-administered drugs and biologicals. In determining the reimbursement methodology for physician-administered drugs and biologicals, Reimbursement for physician-administered drugs and biologicals are based on the lesser of the billed amount, a percentage of the Medicare rate, or one of the following methodologies:

(1) If the drug or biological is considered a new drug or biological (that is, approved for marketing by the Food and Drug Administration within 12 months of implementation as a benefit of Texas Medicaid), it may be reimbursed at an amount equal to 89.5 percent of average wholesale price (AWP).

(2) If the drug or biological does not meet the definition of a new drug or biological, it may be reimbursed at an amount equal to 85 percent of AWP.

(3) Physician-administered drugs purchased under the 340B Drug Program are reimbursed as described under this section of the state plan. Drugs and infusion drugs, may be reimbursed at an amount equal to 106 percent of the average sales price (ASP). Additional information related to physician reimbursement may be found in Attachment 4.19-B, pages 1a to 1a.3 of the Texas Medicaid State Plan.

(M) Investigational drugs are not a current Texas Medicaid pharmacy benefit.
Pharmacy Reimbursement Methodology (continued)

(c) Legend and Nonlegend Medications (continued)

(1) Notice of a public hearing to receive comments on proposed changes to
general pricing determinations derived under these policies shall be
published in the Texas Register.

(2) Definitions. As used in Section IIC, these terms shall be defined as follows:

(N) Reported Manufacturer Price—Information on pricing submitted to VDP by
the manufacturer, including Average Wholesale Prices, Average
Manufacturer Price, wholesaler costs, direct prices and institutional or
contract prices.

(O) Wholesale Costs—The net cost of a product to a drug wholesaler or distributor.